Drugs / SGN-15
SGN-15
also known as
cBR96-Doxorubicin Immunoconjugate · BMS-182248 · BR-96 CBR96-DOXORUBICIN IMMUNOCONJUGATE · BR96
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00086333 | Jul 2004 → Dec 2005 | non-small cell lung carcinoma | Seagen Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00028483 | Oct 2000 → Apr 2003 | female breast carcinoma | Seagen Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT00031187 | Oct 2000 → Jul 2003 | prostate neoplasm | Seagen Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00051571 | ? → Oct 2003 | non-small cell lung carcinoma | Seagen Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00051584 | ? → May 2003 | ovarian neoplasm | Seagen Inc. | Terminated | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SGN-15 | “OUTLINE: Patients receive doxorubicin-monoclonal antibody BR96 immunoconjugate (SGN-15) IV over 2 hours and docetaxel IV over 30 minutes on day 1 of weeks 1-6.” NCT00028483 ↗ |
| Known as | BMS-182248 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2109502 ↗ |
| Known as | BR-96 CBR96-DOXORUBICIN IMMUNOCONJUGATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL2109502 ↗ |
| Known as | BR96 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2109502 ↗ |
| Known as | cBR96-Doxorubicin Immunoconjugate | “A Phase II Study Using SGN-15 (cBR96-Doxorubicin Immunoconjugate) in Combination With Docetaxel for the Treatment of Advanced Stage or Recurrent Non-Small Cell Lung Carcinoma” NCT00051571 ↗3“Combination SGN-15 (cBR96-Doxorubicin Immunoconjugate) and Docetaxel” NCT00086333 ↗ “SGN-15 (cBR96-doxorubicin immunoconjugate)” NCT00031187 ↗ “SGN-15 (cBR96-Doxorubicin Immunoconjugate)” NCT00051584 ↗ |
| Modality | Monoclonal antibody | “monoclonal antibody (mAb) drug conjugate” NCT00031187 ↗ |
| Route | Intravenous | “immunoconjugate (SGN-15) IV over 2 hours” NCT00028483 ↗ |